An Electromechanical Model-Based Study on the Dosage Effects of Ranolazine in Treating Failing HCM Cardiomyocyte.

ABSTRACT:

Background and objective

Hypertrophic cardiomyopathy (HCM) is associated with a significant risk of progression to heart failure (HF). Extensive experimental and clinical research has highlighted the therapeutic benefits of ranolazine in alleviating electrophysiological abnormalities and arrhythmias in the context of HCM and HF. Despite these findings, there is a shortage of studies examining the electromechanical responses of failing HCM cardiomyocytes to ranolazine and the impact of ranolazine dosage on outcomes across varying degrees of HF. This study aims to systematically address these issues.

Methods

A computational modeling approach was utilized to quantify alterations in electromechanical variables within failing HCM cardiomyocytes subsequent to ranolazine treatment.

SUBMITTER: Liu T 

PROVIDER: S-EPMC12018674 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature